DepoMed, Inc. (NASDAQ: DEPO) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $21.22 million versus the consensus estimate of $22.13 million.

Earnings